A Phase 3 interventional study of DE-117B Eye Drops and Latanoprost in Open Angle Glaucoma and Ocular Hypertension, sponsored by Santen Pharmaceutical Co., Ltd.. Active, not recruiting at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2024, is one of 17 in phase 3, and was the 36th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:
Santen SAS · Sites in Austria, Belgium, Germany and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2024.
This study's enrollment of 345 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 165 across the 31 interventional studies, 196 across the 4 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.
1 of the studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.
The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.
It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.
There will be a bridging cohort and extension follow-up phase
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.
Drug: DE-117B Eye Drops
0.005% Latanoprost Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.
Drug: Latanoprost
Investigational Product: 0.002% DE-117B Eye Drops
Active Control: 0.005% Latanoprost Eye Drops
Intraocular Pressure (IOP) at Week 4
Change from Baseline in Mean Diurnal IOP at Week 4
Time frame: Week 4
Percent Change in Intraocular Pressure (IOP)
Percent Change from Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 4
Time frame: Week 4
Change and Percent Change in Intraocular Pressure (IOP)
Change and Percent Change from Baseline in Mean Diurnal IOP at each post baseline visit except week 4.
Time frame: Post baseline Visits except Week 4
Change and Percent Change from baseline in Intraocular Pressure (IOP)
Change and Percent Change from baseline in IOP at each IOP assessment time point at each post baseline visit.
Time frame: Assessment time point at each post baseline visit.
Percentage of Responders
Percentage of Responders (percent reduction from baseline in Mean Diurnal IOP: ≥20%, ≥25%, ≥30%) at each post baseline visit.
Time frame: Each Post Baseline Visit.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Aug 2026, 21 months after the start.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 21 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Pharmaceutical Co., Ltd. →